Evidence map›Paper›PMID 30949852›Full record

ArticleBiomedical microdevices2019

Investigation of parameters that determine Nano-DC vaccine transport.

Jingxin Zhang, Junhua Mai, Feng Li, Jianliang Shen, Guodong Zhang, Jun Li, Louis E Hinkle, Daniel Lin, Xuewu Liu, Zheng Li and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Biomedical microdevices, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Jingxin ZhangDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Junhua MaiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Feng LiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Jianliang ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Guodong ZhangDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Jun LiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Louis E HinkleDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Daniel LinDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Xuewu LiuDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Zheng LiCenter for Bioenergetics, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Rong-Fu WangCenter for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Elizabeth A MittendorfDepartment of Surgery, Brigham and Women's Hospital, Dana-Farber/ Brigham and Women's Cancer Center, Boston, MA, 02115, USA.
Mauro FerrariDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA. mferrari@houstonmethodist.org.
Haifa ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA. hshen@houstonmethodist.org.ORCID http://orcid.org/0000-0002-9728-5430
Houston Methodist · USBrigham and Women's Hospital · US

Funding

Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$9.3M
Mechanism of Intratumoral Transport of Particulate DrugsR01CA222959 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, SHU-HSIA, LIU, XUEWU · 2018 to 2023
$2.3M
Tumor vasculature-targeted nanotherapeutics for DNA damage responseR01CA193880 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA193880NCI NIH HHS R01 CA222959NCI NIH HHS U54 CA210181
6 · The paper itself

Abstract

Effective migration of dendritic cells into the lymphatic system organs is the prerequisite for a functional dendritic cell vaccine. We have previously developed a porous silicon microparticle (PSM)-based therapeutic dendritic cell vaccine (Nano-DC vaccine) where PSM serves both as the vehicle for antigen peptides and an adjuvant. Here, we analyzed parameters that determined dendritic cell uptake of PSM particles and Nano-DC vaccine accumulation in lymphatic tissues in a murine model of HER2-positive breast cancer. Our study revealed a positive correlation between sphericity of the PSM particles and their cellular uptake by circulating dendritic cells. In addition, the intravenously administered vaccines accumulated more in the spleens and inguinal lymph nodes, while the intradermally inoculated vaccines got enriched in the popliteal lymph nodes. Furthermore, mice with large tumors received more vaccines in the lymph nodes than those with small to medium size tumors. Information from this study will provide guidance on design and optimization of future therapeutic cancer vaccines.

Indexed as

NanomedicineAnimalsBiological TransportCancer VaccinesCell Line, TumorDendritic CellsMiceMicrospheresPhagocytesSiliconTissue DistributionTumor BurdenCancer VaccinesSiliconBiodistributionMicroparticleNano-DC vaccineSiliconTransport

Identifiers

PMID30949852
PMCPMC6686196
OpenAlexW2931503105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.